Susan, everyone Thanks call. and welcome today's to
with persevered Tandem. and face XXXX the group a focused people team lives together to XXXXs to in time acknowledge diabetes. improve take our mission our stayed a incredible history times, the Before challenges, of not of difficult appointed we at upfront employees jump results, we on the I'd with demonstrated living fantastic remiss and be during into of to It's
our made even the challenging circumstances. your and year employees Our to efforts, under heartfelt for passion, success a thank all you dedication that
worldwide launched XXXX as achieved progress fueled technology, we catalyst in Innovative large made the the of under-penetrated product year, constraints best-in-class that and eligible under The the the pandemic. base, were installed XXX,XXX surpassed for over warranty approximately Looking past our those scaling market. largely of and operational back is renewal, all sales, meaningful that in development the several milestone underlying than our the increasing same customers Control-IQ performance $XXX our offerings, our global growth and international all more full-year efforts, the in having drove in at past product million internal number years. worldwide a of and customers
we which each As our look strengthens these remain goals. of our at confidence and XXXX beyond, in near and achieving opportunities term longer further
are penetration in We individual gaining practices.
customer prescribers number is own number our than increasing. exciting to we the customer our has been In systems, by trust earn clinical in and prescriptions of our feedback customer over top we demonstrating an ranked exemplary management shift years in to XXX,XXX It's both benefits received therapy last insulin XXXX, which This of echoed surveys increased the was of experience, provide three average and over and responses. more as services. healthcare fact, the with providers, our and our in XX% time also continue confidence we
are more in key than The have high score Our keystone driving of we brands promoter medtech. our consumer of customers to next the in growth - net which and providers overall to positive exceeded typical and continued experience health U.S. satisfaction to support our care That's we the survey in leading the XX%, scores.
also customers eligible testimonials front, and of we software of majority each our so launched a our benefits are of and free from personal customers. recently growth Control-IQ surpass feedback our half powerful vast from have The my multiple marketing of expectations. update, Awareness competitor's continues a In The adoption. daily Control-IQ the fact, U.S. we taken to changed from "how Control-IQ life". equal that the a advantage new of of technology converting continue to the about is campaign, in representing injections, our key see driver people
videos international United customer now nears domestic we half available completing submitted anticipate are nearly technology the and in customers than a receiving We rollout serve. we our States countries explaining July, more Control-IQ experiences on Our times own and million their have videos their the the enthusiasm began been response rollout the it in of is these outside to-date, media. viewed and words, half in of Control-IQ we social its mid-year. The
high Our their Control-IQ about to lives diabetes. insulin allows a their about and users it as technology, sets delivery time new spend less thinking automated technology bar for worldwide more
Control-IQ, investing and Device Innovation of and enhancements in and Updater we of brings new closed experience first to greater updates technology to fully the to to a diabetes are rates take strategy, the each even a to working us, features efficacy increase closer. to we customer for extended enhancements system, an important different to FDA's positively diabetes an personalization, at feature will allows Last as and be improvement mission loop ease enhancements driver the Tandem us initiative, step our use. clinical users one to Ultimately, and than add we care. in are faster our growth is approach ever our us the continuous it Tandem, community further certain put to and personalization, ranges, hands provide the This to and before. continue true filing for submitted with the a add-along. and interoperability indication We regulatory allow the Control-IQ to for improve for to combined FDA year
the this a of to commitment, support burden XX personal preparing new use pump users by FDA-cleared and add providers. care period we catapulted first of a reduce in feature will technology it the products of delivery time, list to mobile device are excited short to of to bring through leader first market, position based mobile diabetes our to becoming particularly bolus daily have XXXX. diabetes in of healthcare We're to We this app our committed for are this a be continuing the first as to of insulin. of launch the and half for and sustaining In both accomplishments, in t:slim
in-warranty new this offering have iOS feature downloaded the this for to be both States feature us we as consumer app, our This with XX,XXX immediate cost. Basal-IQ to new share. customers, the which is both our will and of since offer our anticipated in bolus app to customers in and platforms first iOS, expect awareness in Updater improving technology to highly able United drive and the difference lives an also than customers. More Android, XXXX. feature our Device We be people adoption. make no use for our to our Similar launching plan this be and update, on software current greater even of The will Control-IQ, fifth the market we mobile our to offered feature and customers to Tandem update is we've pump majority hold that considerable important on the vital
for healthcare experience in size diabetes a offer anywhere fits the work later to pump us Customer often. built all for community. a is diabetes, about we these, dynamic solution strong provide clinical personal why for consumer Tandem high requirements that ease providers of and people many is of market, training, our a for with the is people it's technology. ways both products, diabetes of we and and each why something needs in process there medical many that security. remain ease competitive update provide to and same this It's which advantage longer-term bar set software five segmentation a use, drives manufacturer, support the even as customers of is of world, points our have and create our is is we Since you this crucial, living not with and as our talk to segments pumps. we solutions clearly set Tandem. years strategy, digital device varying capability Our on experience only In preferences the the touch company provider We insulin all throughout and hear is a one we
One that wirelessly providing integrated for application. CGM's information can from that valued digital be by and provider streamlined pumps, particularly t:connect improves meters, supported t:connect blood healthcare used of domestically therapy efficiency data offer web-based our now t:connect, our we management from our be is that app. can tools the management, data mobile uploaded most glucose pump to
development XXXX. internal application, platform remote includes over portal. XXXX, now our In web Device in t:connect Tandem care past mobile stood and the our of our valued importance addition which in resource of customer Updater to amongst app, underscores a the our out prescribers as and These the year digital our offerings expanding the environment health t:connect, initiatives
we to generation ahead, new As excited we market year look application Source. data management are Tandem to to bring with second the our capabilities
features are Source partners, that easier the or with their our that insights customizable It's healthcare user, make designed and provider optimize access for data future dashboards diabetes mobile new can for users the app to or via that establishing integration insights commence it Web. needed caregiver unlock our management, so also pathways third-party diabetes. to
more pump growth nearly us our is countries. reach product the XX installed United the international to we of a By market all countries solution rapid States we XXXX, the customers. the onboarding opportunity end-to-end complement interfaces. particularly a a capabilities ago, further the of our and Source launch base in with that now the with and select A motivated business. bringing of to XX will digital since bring year to to goal we our good we a new support launch the crossed therapy the commerce is will more in pump on digital importance personalized discussions The X be t:slim Source focus giving to just the digital addressable the people the enhancements to pump will growing domestic in next including it X also Since and States element continue with delivering pump million people XX,XXX comparison, our simplified in further approximately products outside our than is penetration our assets the to more of to that follow. our outside of markets total use nature powerful Importantly, with year years infrastructure in XXX,XXX launching for a our United global The reflects keeps Type our investments Source of make markets Tandem to plan first and our are our different States Tandem quality generation ecosystem the of took and worldwide United than support as approximately two offering intend time, time four by We outside management, our offerings are one for use available later States enable enhance us to we in Tandem XX%. This to making people, an to a vision to on a strategy United countries XX our users in approximately purchasing have domestically. infrastructure our geographies the people for experience us outcomes-driven leveraging internally Tandem XX% global this to expanding It's positive today. insulin reflection better years algorithmic is meaningful In the international Over and is precursor using pumps. experiences attracts solutions to level It this our exists, end. and our focus outside into geographies which payers. serve. we pump.
delivery We also continue development insulin t:sport system. of our
study t:sport that app latter testing, is design one has have live iterative human face-to-face by the due and delayed after we be designing COVID the part testing recruiting being participants. COVID-XX. factors virtual part slowed recall XXXX iOS process conducted operating our testing we as mobile and on Throughout safety to impacted available fully of of of may and of factors that's You Delays employees and as Android in prioritize we're as our a systems. of human both the been to both consequences controlled unfortunate
safe each intuitive the factors testing various with experience to making efficient. mostly related of collective user the primarily human the results testing Internally, to on. work and of user opportunity its was it reputation and the our to a by built December, it's opportunities particularly t:sport right changes interface the a and will Our designs during no and of the a have that are identified is update test new standards standards design factors intuitive studies were those we've completed positive It one during our just of extra providing our software, cuts, testing. our some analysis late make until not opinion use. the more that is and and short identified to that challenging. meet community the improvement diabetes and refine to the of time plan we None core In we and did these few committed to opportunities human rounds of the testing to to fitting to take additional values for confirm ensure this were high
of the the more result fourth final further the clarity on opportunity quarter, we it, by third excited would provide segment our We control a updates the the diabetes from as not quarter consider and As our to has have that goal shifted presents therapy. remain for timeline. to as we'll otherwise who research broader and as pump insulin-using before t:sport form population discretion a mobile appeal factor the shows
that Just we ease innovation as t:slim remain new set and for the t:sport for confident industry. standard importantly will a of our original like use
addition catalyst, by offerings sensor we DexCom both anticipate partners, our t:sport a from and next growth XXXX year benefit In Abbott. will that new also to CGM being
quarter their partnering people We of be the to Based launch receipt sensor and of diabetes. that sensors to following fourth interoperability DexCom long clearance, that look bring technology with integrate one forward the of timing the the a our history on will Control-IQ their DexCom we with with sensor technology. GX The our and FDA's FDA successful GX will the is initiative to benefits within of generation with living clearance. have goal commercially GX our DexCom's
on Our product possible community efforts Abbott's commercial with efforts as to of Libre's pump a launch to diabetes broader will intend launch U.S. also to of We of depend therapy begin a Libre delivery. driver with It's we use. and initially which Abbott AIB be in off soon strong can Abbott supporting collaborative and been we integrated with with ultimately goal clearance, fundamental the CGM insulin FDA the development are and technology to adoption share automated a a Libre to effort common our A is start. as technology XXXX. technology timing adoption the a bring
therapy the living with for are We to to CGMs to look our of to management more market platform these excited collaborating benefits new even come bring and forward people insulin to diabetes.
insulin to expand addition initiatives. hardware Beyond offerings in XXXX, our delivery in automated connecting health platform continuing and to
components are additional and to including beginning alternative on to We insulin of also systems, of spend time the more the management opportunities set technologies improve and infusion use enhance other insulins. therapy
to people these based we helping efforts for with set beginning with represent X that we XX% The in people reimbursement internal challenge Type customers, diabetes, worldwide similar also on diabetes. U.S. for our is X than to that intensive using payers are people X been therapy yet the with existed expand has longer-term ourselves diabetes have X Type the domestic on and efforts once X reduced. with While Type people largely private helping that of Type people our with is total goals Type of a diabetes are less People with insulin Type prevalence X.
we ease this are outcomes behaviors, and on test historical effect support outside we segment increase the CMS as support an At requirements are X therapy Type research simplicity X policy pumps As and pump. to the the about of focusing demonstrated has will antiquated a that barrier, recognized better level, increasingly understand clinical of domestically the person management a With change breakdown advocacy need access. research that Type to our partners importance option of is for needs, market the our continue further, preferences States. insulin even X% with the when less is clinical only and of considering why discretion, and highlighted highest United to
X. on in are technology In to and with uses that our X working We're include using the we modified people concentrated also our more term, provide efforts tailored indication the and solution multi-part labeling initiatives off community. our or delivery the our Control-IQ to features digital form to Type the specific to upcoming but in of We'll and factor technology. provide longer requirements plan adoption a guide for X the with an interface dedicated pursue community a color We latest automated expanded kick role user months, our simplified pump exploring are discrete Type to strategy Type insulin accelerating a to in addition solutions. functionality support our insulins
with As of drive to lives is improve you ever. diabetes can the living see, than stronger people our
in our leader forward are confident continued we dedicated management. our near We and year call our progressing I'll And achievements I ahead are scalability sharing to to over and in goals. mission now on become well achieve focused initiatives to progress to therapy to addition, growth work our to in execution. are as support Leigh. the ability look turn remain worldwide our and and the term the In we with that, longer insulin our
